China NDA 2026 - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

What the latest UTOPIA trial data reveal about UGN-103’s competitive position in LG-IR-NMIBC

Delivery Hero (DHER) stock up 4% to €29.5 as Aspex forces CEO exit and Korea sale opens

What the RIDGE-1 interim results reveal about the future of cardiac gene therapy in ARVC

Hanwha Aerospace targets NATO demand with Romania unmanned systems push at BSDA 2026

Read More

Pharma Industry News

Denifanstat phase 3 acne trial success positions Ascletis for China NDA submission in 2026

Find out how Denifanstat’s Phase 3 acne trial success positions Ascletis Pharma for a 2026 China NDA submission and reshapes the acne-therapy market.

bySoujanya Ravi

October 24, 2025

web analytics